Source: Contract Pharma

Nested Therapeutics: HitGen, Nested Therapeutics Ink Research Service Agreement

HitGen will utilize its DNA-encoded library technology platform for the design, synthesis, and screening of DELs.

Read full article »
Nested Therapeutics's Competitors | Nested Therapeutics's News | Nested Therapeutics's Financials
Stay up-to-date with the latest news on Nested Therapeutics
Est. Annual Revenue
$5.0-25M
Est. Employees
25-100
Darrin Miles's photo - CEO of Nested Therapeutics

CEO

Darrin Miles

CEO Approval Rating

90/100

Read more
Stay up-to-date with the latest news on Nested Therapeutics